Global Dry Powder Inhaler Devices Pipeline Assessment Report 2020: Major Players, Product Description, Licensing and Collaboration Details and Developmental Activities – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Dry Powder Inhaler Devices – Medical Devices Pipeline Assessment, 2020” report has been added to ResearchAndMarkets.com’s offering.

“Dry Powder Inhaler Devices – Medical Devices Pipeline Assessment, 2020”. Dry powder inhaler devices deliver medication to the lungs in the form of a dry powder.

Scope

• Extensive coverage of the Dry Powder Inhaler Devices under development
• The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
• The report reviews the major players involved in the development of Dry Powder Inhaler Devices and list all their pipeline projects
• The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
• The report provides key clinical trial data of ongoing trials specific to pipeline products
• Recent developments in the segment / industry

Reasons to Buy

• Formulate significant competitor information, analysis, and insights to improve R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand important and diverse types of Dry Powder Inhaler Devices under development
• Develop market-entry and market expansion strategies
• Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
• In-depth analysis of the product’s current stage of development, territory and estimated launch date

Key Topics Covered:

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Introduction

2.1 Dry Powder Inhaler Devices Overview

3 Products under Development

3.1 Dry Powder Inhaler Devices – Pipeline Products by Stage of Development

3.2 Dry Powder Inhaler Devices – Pipeline Products by Territory

3.3 Dry Powder Inhaler Devices – Pipeline Products by Regulatory Path

3.4 Dry Powder Inhaler Devices – Pipeline Products by Estimated Approval Date

3.5 Dry Powder Inhaler Devices – Ongoing Clinical Trials

4 Dry Powder Inhaler Devices – Pipeline Products under Development by Companies

4.1 Dry Powder Inhaler Devices Companies – Pipeline Products by Stage of Development

4.2 Dry Powder Inhaler Devices – Pipeline Products by Stage of Development

5 Dry Powder Inhaler Devices Companies and Product Overview

5.1 Adamis Pharmaceuticals Corp Company Overview

5.1.1 Adamis Pharmaceuticals Corp Pipeline Products & Ongoing Clinical Trials Overview

5.2 Advent Pharmaceuticals Pty Ltd Company Overview

5.2.1 Advent Pharmaceuticals Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview

5.3 Aespira Ltd. Company Overview

5.4 AKELA Pharma Inc. (Inactive) Company Overview

5.4.1 AKELA Pharma Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview

5.5 AstraZeneca Plc Company Overview

5.5.1 AstraZeneca Plc Pipeline Products & Ongoing Clinical Trials Overview

5.6 Bayer AG Company Overview

5.6.1 Bayer AG Pipeline Products & Ongoing Clinical Trials Overview

5.7 Boehringer Ingelheim International GmbH Company Overview

5.8 Circassia Group Plc Company Overview

5.8.1 Circassia Group Plc Pipeline Products & Ongoing Clinical Trials Overview

5.9 Creare LLC Company Overview

5.9.1 Creare LLC Pipeline Products & Ongoing Clinical Trials Overview

5.10 Eli Lilly and Co Company Overview

5.10.1 Eli Lilly and Co Pipeline Products & Ongoing Clinical Trials Overview

5.11 GlaxoSmithKline Plc Company Overview

5.11.1 GlaxoSmithKline Plc Pipeline Products & Ongoing Clinical Trials Overview

5.12 Hovione Technology Ltd Company Overview

5.13 Iconovo AB Company Overview

5.13.1 Iconovo AB Pipeline Products & Ongoing Clinical Trials Overview

5.14 Liquidia Technologies Inc Company Overview

5.14.1 Liquidia Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview

5.15 Lupin Pharmaceuticals Inc Company Overview

5.15.1 Lupin Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview

5.16 MannKind Corp Company Overview

5.16.1 MannKind Corp Pipeline Products & Ongoing Clinical Trials Overview

5.17 Monash University Company Overview

5.17.1 Monash University Pipeline Products & Ongoing Clinical Trials Overview

5.18 Nektar Therapeutics Company Overview

5.18.1 Nektar Therapeutics Pipeline Products & Ongoing Clinical Trials Overview

5.19 Ology Bioservices Inc Company Overview

5.19.1 Ology Bioservices Inc Pipeline Products & Ongoing Clinical Trials Overview

5.20 OPKO Health Inc Company Overview

5.20.1 OPKO Health Inc Pipeline Products & Ongoing Clinical Trials Overview

5.21 OtiTopic LLC Company Overview

5.21.1 OtiTopic LLC Pipeline Products & Ongoing Clinical Trials Overview

5.22 Pharmaxis Ltd Company Overview

5.22.1 Pharmaxis Ltd Pipeline Products & Ongoing Clinical Trials Overview

5.23 Quench Medical Inc Company Overview

5.23.1 Quench Medical Inc Pipeline Products & Ongoing Clinical Trials Overview

5.24 Respira Therapeutics Inc Company Overview

5.24.1 Respira Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview

5.25 Sandoz International GmbH Company Overview

5.25.1 Sandoz International GmbH Pipeline Products & Ongoing Clinical Trials Overview

5.26 Sheffield Hallam University Company Overview

5.26.1 Sheffield Hallam University Pipeline Products & Ongoing Clinical Trials Overview

5.27 Spyryx Biosciences Inc Company Overview

5.27.1 Spyryx Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview

5.28 Sun Pharma Advanced Research Company Ltd Company Overview

5.28.1 Sun Pharma Advanced Research Company Ltd Pipeline Products & Ongoing Clinical Trials Overview

5.29 University of Kansas Company Overview

5.29.1 University of Kansas Pipeline Products & Ongoing Clinical Trials Overview

5.30 University of Sydney Company Overview

5.30.1 University of Sydney Pipeline Products & Ongoing Clinical Trials Overview

5.31 University of Texas Medical Branch at Galveston Company Overview

5.31.1 University of Texas Medical Branch at Galveston Pipeline Products & Ongoing Clinical Trials Overview

5.32 Vectura Group Plc Company Overview

5.32.1 Vectura Group Plc Pipeline Products & Ongoing Clinical Trials Overview

5.33 Verona Pharma Plc Company Overview

5.33.1 Verona Pharma Plc Pipeline Products & Ongoing Clinical Trials Overview

5.34 Virginia Commonwealth University Company Overview

5.34.1 Virginia Commonwealth University Pipeline Products & Ongoing Clinical Trials Overview

6 Dry Powder Inhaler Devices – Recent Developments

7 Appendix

For more information about this report visit https://www.researchandmarkets.com/r/j68m94

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900